Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Significant Decline in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) saw a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 100 shares, a drop of 97.6% from the May 15th total of 4,100 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Basilea Pharmaceutica Price Performance

Shares of BPMUF remained flat at $57.70 during mid-day trading on Friday. Basilea Pharmaceutica has a 52 week low of $47.50 and a 52 week high of $57.70. The business has a 50-day simple moving average of $49.79 and a two-hundred day simple moving average of $51.87. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.10 and a quick ratio of 3.27.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.